Top Pharmaceutical Companies in Los Angeles, CA (61)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Profitability: Adjusted EBITDA remained robust in 2025 (about $270M, ~34% margin) and 2026 guidance was lifted to $240–$250M, indicating healthy margins despite softer top-line trends. Strong quarterly EBITDA and cash generation in 1H 2026 underscore financial durability through the transition.
Diversified Revenue Streams: Pharma Direct and subscriptions are scaling quickly (Pharma Direct +41% in 2025 and +76–82% YoY in 1H 2026; subscriptions +16% in Q1 and +39% in Q2 2026), broadening the mix beyond the legacy coupon business. Management continues to position these segments as key growth drivers that can offset core declines over time.
Product Line Growth: New offerings such as condition‑specific programs (notably weight‑loss/GLP‑1), the GoodRx Companion membership, and initiatives like Employer Direct expand the product footprint. Deeper manufacturer relationships and program integrations (including presence on the federal TrumpRx.gov platform) further extend the solution set.
At Solventum, we enable better, smarter, safer healthcare to improve lives. We never stop solving for you
Solventum's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader or co‑leader in core niches such as negative‑pressure wound therapy and hospital coding/CDI software, with widely deployed platforms and recognized standings. Brand strength and installed bases across MedSurg, Dental, and HIS reinforce competitive positioning.
Resilient & Sustainable Growth: Recent quarters show positive organic sales growth, and guidance points to continued low‑single‑digit expansion. Feedback suggests momentum is supported across key segments, aligning with a steady, incremental trajectory.
Future-Ready Strategy: Management outlines a multi‑year plan centered on portfolio focus, R&D‑led innovation, and selective M&A to accelerate growth. Actions such as SKU rationalization, product launches, and targeted partnerships indicate preparation for longer‑term expansion.
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism...
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have...
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as...
Daiichi Sankyo's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate sustained year-over-year revenue increases driven primarily by the oncology franchise, notably ENHERTU and DATROWAY. Management maintains forward revenue growth guidance while highlighting continued indication and geographic expansion for these assets.
Strategic Partnerships: Large, multi‑asset collaborations with AstraZeneca and Merck validate the DXd platform and provide capital, development support, and commercial reach. These alliances underpin scale‑up and reinforce the medium‑term growth outlook in oncology.
Strong Market Position & Advantage: The company is recognized as a leader in oncology antibody‑drug conjugates, with ENHERTU establishing leading shares in key indications and additional approvals broadening use. Category leadership is further supported by expanding first‑line and tumor‑agnostic indications.
Thrivelab is a telehealth-based provider of evidence-based hormone and testosterone balancing programs as well as natural bioidentical products to alleviate age-related symptoms and restore youthful vitality.
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is a leading nonprofit research organization focused on biomedical innovation, translating discovery into health impact through research, education, and community outreach.
We’re designing a better way to deliver and pay for health while engaging and guiding a community of members to live their best health. As a national, team-based medical group with a focus on wellbeing and prevention that extends beyond traditional sick care, we deliver Primary Health. An entirely new model of health, Primary Health is driven by an interdisciplinary...
O POSITIV is about feeling your best. We make vitamins for real people, in real life, with the belief that small acts of self-care produce positive outcomes. Because personal health should be effortless and intentional
Medela Potentia is an Indonesian integrated healthcare distribution platform serving customers nationwide and in Cambodia. Through its subsidiaries, it distributes pharmaceuticals, consumer-health products, medical devices, cosmetics, beauty and baby products; supports medical-equipment availability through distribution and manufacturing; and operates digital pharmacy and e-commerce capabilities. The company aims to become a trusted global healthcare group by strengthening supply-chain infrastructure, technology, product...
Amerita, Inc. is a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. This market is expanding rapidly and is driven by increasing healthcare costs that are moving patients into the most cost-effective delivery settings, a growing bio-pharmaceutical pipeline of
Meissner manufactures advanced microfiltration and single-use systems. Focused on fluid technology and innovation, we leverage our R&D efforts to offer our clients products that deliver advanced processing and fluid handling solutions for pharmaceutical and biopharmaceutical manufacturing. To find out more about Meissner, visit www.meissner.com. If you are interested in pursuing a career at Meissner, please visit www.meissner.com/careers.
TIENS Group is a global multinational conglomerate founded in 1995 by Li Jinyuan in Tianjin, China. The company specializes in biotechnology, health management, and wellness, operating in over 190 countries. It offers a wide range of dietary supplements, healthcare equipment, and beauty products, aiming to improve global health by integrating nature with modern science and technology to provide a better...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
.png){kind=logo}
Avid Bioservices is transforming the CDMO experience, with more than 30 years of unrivaled experience manufacturing biologics, and world-class mammalian protein facilities. We’ve produced more than 250 commercial batches, and 5 commercial products marketed in 90+ countries. For more than 10 years, we’ve maintained a flawless quality track record which we’re committed to uphold. We do it right the first...
Avid Bioservices's Top Stability & Growth Strengths
Strong Revenue Growth: Recent quarters show year-over-year revenue gains, a record-high backlog above $200 million, and reiterated FY2025 guidance pointing to mid‑teens growth. Sequential momentum and new bookings indicate improving demand conversion.
Investor Backing & Capital Strength: The $1.1 billion take‑private by GHO Capital and Ampersand, along with debt refinancing to 2029, provides growth capital and financial flexibility. External sponsors explicitly plan to fund expansion in capabilities, talent, and reach.
Future-Ready Strategy: Multi‑year capacity expansions lifted estimated annual revenue capacity to $400M+, and new cell and gene therapy facilities position the company in high‑demand modalities. Leadership changes and added roles signal a focus on scaling and modernization.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global...
